Search PubMed⌕ Search

Biomedical subjects

J Heath

Publications and source records attributed to J Heath.

81 records · Page 5Linked to original sources

Toxicology of n-pentane (CAS no. 109-66-0).

n-Pentane (CAS no. 109-6-0) is a hydrocarbon solvent with an estimated production volume of 50000 metric tons in Europe. The present work was carried out to strengthen the toxicological information available for regulatory decision-making, particularly product classification, occupational exposure limits and risk assessment. The work described in this report was sponsored either by the Pentane Special Interest Group under the auspices of the Hydrocarbon Solvent Producers Association of CEFIC (European Chemical Industry Council) or by Exxon Chemical Europe. The following results were obtained: n-pentane was not acutely toxic by oral or inhalation routes, it was not a skin or eye irritant and did not induce skin sensitization. It did not exhibit cumulative toxicity at levels up to 20000 mg m(-3), which is approximately one-half of the lower explosive limit and the highest level considered safe to test. It did not induce developmental toxicity and was not mutagenic. From this and other existing information, it is concluded that n-pentane does not require classification for potential toxic hazards (as defined by Annex VI of the EU Dangerous Substance Directive, 1993), although the physical properties indicate that it would be appropriate to warn for the potential for aspiration. Further, there is no reason to reduce the current occupational exposure recommendations. Finally, although there are some safety issues relating to the flammability of n-pentane, the absence of any demonstrable toxicity at high treatment levels indicates that the risk of adverse health effects is minimal for all segments of the population.

Administration, Inhalation↗

Coronary and peripheral vascular resistance in the anaesthetized diabetic sheep.

To determine whether vascular resistance was altered in diabetes, the vascular resistance in both the peripheral arterial bed and the circumflex coronary artery was compared in six normal and five diabetic adult sheep, under pentobarbitone anaesthesia. Diabetes induced by alloxan significantly increased blood glucose (15.6 mmol/l, s.e.m. = 2.8, vs 5.5 mmol/l, s.e.m. = 0.6; P greater than 0.001) compared with controls. Systolic blood pressure was lower in diabetics (92 mmHg, s.e.m. = 12, vs 123 mmHg, s.e.m. = 5; P less than 0.025) as was diastolic blood pressure (73 mmHg, s.e.m. = 15, vs 104 mmHg, s.e.m. = 4; P greater than 0.05). Basal peripheral resistance was lower in diabetics than controls (36.0 mmHg.min/l, s.e.m. = 7.9, vs 42.3 mmHg.min/l, s.e.m. = 2.8), but not significantly so. Methoxamine markedly increased peripheral vascular resistance in both groups, but did not change coronary vascular resistance, due to autoregulation. The dose-response curves of peripheral or coronary arteries to methoxamine showed no significant difference between diabetic and control sheep. Dose-response curves for isoprenaline and noradrenaline infusion suggested there may be altered beta-receptor sensitivity in diabetes. In conclusion, there are marked differences in the vascular beds of diabetic and normal sheep under basal conditions. In contrast to previous studies, alpha-adrenoceptors are not different in diabetics, but further studies in unanaesthetized animals are indicated, as beta-receptor sensitivity may be altered in diabetes.

Acetylcholine↗

Utilization of an elastomeric continuous infusion device to maintain catheter patency.

The frequency of vascular access device (VAD) complications increases with the complexity of therapy or poor catheter maintenance. Catheter occlusions are most frequently caused by inadequate catheter flushing or technique. The study group of 25 patients was placed on an elastomeric continuous infusion device with patient costs and occlusion rates compared with historic data. The use of the elastomeric continuous infusion device saved an average of $123 per week when compared with traditional flushing devices, which cost from $216 to $248 per week. The incidence of catheter patency loss was reduced by 50%. The nurses also reported considerable timesaving in catheter maintenance and patient education and an overwhelmingly positive response from staff and patients.

Catheterization, Peripheral↗